Ieq Capital LLC acquired a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 363,494 shares of the company’s stock, valued at approximately $11,134,000.
Several other institutional investors have also added to or reduced their stakes in the business. Focus Advisor Solutions LLC purchased a new position in Caris Life Sciences in the 3rd quarter worth about $1,785,000. Voya Investment Management LLC boosted its holdings in shares of Caris Life Sciences by 519.8% during the 3rd quarter. Voya Investment Management LLC now owns 72,824 shares of the company’s stock valued at $2,231,000 after acquiring an additional 61,074 shares during the last quarter. Rothschild Investment LLC grew its stake in shares of Caris Life Sciences by 10,664.0% in the third quarter. Rothschild Investment LLC now owns 36,490 shares of the company’s stock worth $1,118,000 after acquiring an additional 36,151 shares during the period. Ground Swell Capital LLC bought a new stake in shares of Caris Life Sciences in the third quarter worth approximately $282,000. Finally, Virtus Advisers LLC bought a new stake in shares of Caris Life Sciences in the third quarter worth approximately $343,000.
Caris Life Sciences Stock Down 5.2%
CAI opened at $17.58 on Friday. The company has a current ratio of 6.71, a quick ratio of 5.84 and a debt-to-equity ratio of 0.61. Caris Life Sciences, Inc. has a 1-year low of $14.19 and a 1-year high of $36.50. The company has a market capitalization of $5.04 billion, a PE ratio of 53.27, a PEG ratio of 5.73 and a beta of 0.71. The firm’s 50 day simple moving average is $28.87 and its two-hundred day simple moving average is $21.58.
Caris Life Sciences (NASDAQ:CAI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a return on equity of 16.00% and a net margin of 9.16%. The firm had revenue of $275.36 million during the quarter. During the same quarter last year, the company earned $0.08 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. As a group, equities analysts forecast that Caris Life Sciences, Inc. will post 0.11 EPS for the current year.
Insider Buying and Selling
In related news, insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total value of $238,650.00. Following the completion of the transaction, the insider owned 174,855 shares of the company’s stock, valued at approximately $5,563,886.10. This represents a 4.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President David Spetzler sold 119,212 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.76, for a total transaction of $2,951,689.12. Following the completion of the transaction, the president directly owned 1,182,871 shares of the company’s stock, valued at $29,287,885.96. This represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 1,004,712 shares of company stock valued at $27,205,419. 50.00% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Piper Sandler increased their price objective on shares of Caris Life Sciences from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, November 10th. UBS Group set a $38.00 target price on shares of Caris Life Sciences in a research report on Thursday, November 5th. BTIG Research reiterated a “buy” rating and set a $38.00 target price on shares of Caris Life Sciences in a research note on Thursday, November 5th. Citigroup increased their price target on Caris Life Sciences from $28.00 to $36.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Evercore reissued an “outperform” rating and set a $26.00 price target on shares of Caris Life Sciences in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.18.
Get Our Latest Stock Report on Caris Life Sciences
Caris Life Sciences Company Profile
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
See Also
- Five stocks we like better than Caris Life Sciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding CAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report).
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
